000153107 001__ 153107
000153107 005__ 20240229123039.0
000153107 0247_ $$2doi$$a10.1080/08916934.2019.1710134
000153107 0247_ $$2pmid$$apmid:31933381
000153107 0247_ $$2ISSN$$a0891-6934
000153107 0247_ $$2ISSN$$a1026-7859
000153107 0247_ $$2ISSN$$a1607-842X
000153107 0247_ $$2altmetric$$aaltmetric:76757680
000153107 037__ $$aDKFZ-2020-00189
000153107 041__ $$aeng
000153107 082__ $$a610
000153107 1001_ $$0P:(DE-He78)816f10fe44243f27b2b9a15d421dd186$$aLink, Corinna$$b0$$eFirst author$$udkfz
000153107 245__ $$aAnnexin-coated particles induce antigen-specific immunosuppression.
000153107 260__ $$aAbingdon$$bTaylor & Francis Group$$c2020
000153107 3367_ $$2DRIVER$$aarticle
000153107 3367_ $$2DataCite$$aOutput Types/Journal article
000153107 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1601362218_28911
000153107 3367_ $$2BibTeX$$aARTICLE
000153107 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000153107 3367_ $$00$$2EndNote$$aJournal Article
000153107 500__ $$a#EA:D030#LA:D030#2020 Mar;53(2):86-94
000153107 520__ $$aApoptotic cells mediate the development of tolerogenic dendritic cells (DC) and thus facilitate induction and maintenance of peripheral tolerance. Following the identification of the evolutionary conserved annexin core domain (Anx) as a specific signal on apoptotic cells which antagonises Toll-like receptor (TLR) signalling, we examined whether the tolerogenic capacity of Anx can be exploited to downregulate antigen-specific immune responses. The treatment of bone marrow-derived dendritic cells (BMDC) with particles harbouring Anx as well as the model antigen ovalbumin (OVA) attenuated the response of OVA-specific OT-II T cells. The co-culture of Anx-particle-treated DC and T cells resulted in an anergy-like phenotype characterized by reduced proliferation and cytokine secretion. Here we demonstrate that the anti-inflammatory effects of Anx which are mediated through DC can be used as a tool to generate a particle-based antigen delivery system that promotes antigen-specific immunosuppression. Such Anx-particles may be a new therapeutic approach for the treatment of autoimmune diseases.
000153107 536__ $$0G:(DE-HGF)POF3-314$$a314 - Tumor immunology (POF3-314)$$cPOF3-314$$fPOF III$$x0
000153107 588__ $$aDataset connected to CrossRef, PubMed,
000153107 7001_ $$0P:(DE-He78)2ca78bdce0a4f5d0da65373efc2dd7fa$$aBujupi, Fatmire$$b1$$udkfz
000153107 7001_ $$0P:(DE-He78)92492c6eae05ee58973fc142c9201e3d$$aKrammer, Peter H$$b2$$udkfz
000153107 7001_ $$0P:(DE-He78)4dca42511637e2f9d25519745fa3c697$$aWeyd, Heiko$$b3$$eLast author$$udkfz
000153107 773__ $$0PERI:(DE-600)2031170-9$$a10.1080/08916934.2019.1710134$$gp. 1 - 9$$n2$$p86-94$$tAutoimmunity$$v53$$x1607-842X$$y2020
000153107 909CO $$ooai:inrepo02.dkfz.de:153107$$pVDB
000153107 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)816f10fe44243f27b2b9a15d421dd186$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000153107 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2ca78bdce0a4f5d0da65373efc2dd7fa$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000153107 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92492c6eae05ee58973fc142c9201e3d$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000153107 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4dca42511637e2f9d25519745fa3c697$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000153107 9131_ $$0G:(DE-HGF)POF3-314$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTumor immunology$$x0
000153107 9141_ $$y2020
000153107 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000153107 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000153107 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000153107 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAUTOIMMUNITY : 2017
000153107 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000153107 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000153107 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000153107 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000153107 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000153107 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000153107 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000153107 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000153107 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000153107 9202_ $$0I:(DE-He78)D030-20160331$$kD030$$lD030 Immungenetik$$x0
000153107 9200_ $$0I:(DE-He78)D030-20160331$$kD030$$lD030 Immungenetik$$x0
000153107 9201_ $$0I:(DE-He78)D030-20160331$$kD030$$lD030 Immungenetik$$x0
000153107 980__ $$ajournal
000153107 980__ $$aVDB
000153107 980__ $$aI:(DE-He78)D030-20160331
000153107 980__ $$aUNRESTRICTED